36 results on '"Guo, Jiao"'
Search Results
2. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine
- Author
-
Guo, Jiao
- Published
- 2017
- Full Text
- View/download PDF
3. Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease
- Author
-
Ye, De-wei, Rong, Xiang-lu, Xu, Ai-min, and Guo, Jiao
- Published
- 2017
- Full Text
- View/download PDF
4. Tianhuang formula regulates adipocyte mitochondrial function by AMPK/MICU1 pathway in HFD/STZ-induced T2DM mice.
- Author
-
Luo, Duosheng, Zhao, Yaru, Fang, Zhaoyan, Zhao, Yating, Han, Yi, Piao, Jingyu, Rong, Xianglu, and Guo, Jiao
- Subjects
ADIPOSE tissue physiology ,MITOCHONDRIAL physiology ,CALCIUM metabolism ,BIOLOGICAL models ,REVERSE transcriptase polymerase chain reaction ,ENERGY metabolism ,FASTING ,STATISTICS ,HERBAL medicine ,AMP-activated protein kinases ,ANIMAL experimentation ,WESTERN immunoblotting ,ONE-way analysis of variance ,BLOOD sugar ,MITOCHONDRIA ,CELLULAR signal transduction ,TYPE 2 diabetes ,FAT cells ,GENE expression profiling ,DESCRIPTIVE statistics ,MOLECULAR structure ,DATA analysis ,CHINESE medicine ,MICE ,DIETARY fats ,INSULIN resistance ,LIPIDS ,THERAPEUTICS - Abstract
Background: Tianhuang formula (THF) is a Chinese medicine prescription that is patented and clinically approved, and has been shown to improve energy metabolism, but the underlying mechanism remains poorly understood. The purpose of this study is to clarify the potential mechanisms of THF in the treatment of type 2 diabetes mellitus (T2DM). Methods: A murine model of T2DM was induced by high-fat diet (HFD) feeding combined with low-dose streptozocin (STZ) injections, and the diabetic mice were treated with THF by gavaging for consecutive 10 weeks. Fasting blood glucose (FBG), serum insulin, blood lipid, mitochondrial Ca
2+ (mCa2+ ) levels and mitochondrial membrane potential (MMP), as well as ATP production were analyzed. The target genes and proteins expression of visceral adipose tissue (Vat) was tested by RT-PCR and western blot, respectively. The underlying mechanism of the regulating energy metabolism effect of THF was further explored in the insulin resistance model of 3T3-L1 adipocytes cultured with dexamethasone (DXM). Results: THF restored impaired glucose tolerance and insulin resistance in diabetic mice. Serum levels of lipids were significantly decreased, as well as fasting blood glucose and insulin in THF-treated mice. THF regulatedm Ca2+ uptake, increased MMP and ATP content in VAT. THF increased the mRNA and protein expression of AMPK, phosphorylated AMPK (p-AMPK), MICU1, sirtuin1 (SIRT1) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). THF could increase them Ca2+ level of 3T3-L1 adipocytes and regulate mitochondrial function. The protein expression of AMPK, p-AMPK,m Ca2+ uniporter (MCU) and MICU1 decreased upon adding AMPK inhibitor compound C to 3T3-L1 adipocytes and the protein expression of MCU and MICU1 decreased upon adding the MCU inhibitor ruthenium red. Conclusions: These results demonstrated that THF ameliorated glucose and lipid metabolism disorders in T2DM mice through the improvement of AMPK/MICU1 pathway-dependent mitochondrial function in adipose tissue. Highlights: • AMPK-MCU/MICU1 mediatedm Ca2+ uptake in adipose tissue played an important role in insulin resistance • THF restored impaired glucose tolerance and insulin resistance in diabetic mice induced by HFD/STZ • THF improved the mitochondrial function of in T2DM mice via AMPK-MICU1 pathway [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Fu Fang Zhen Zhu Tiao Zhi Capsules Protect against Myocardial Ischemia by Inhibiting Cardiomyocyte Pyroptosis.
- Author
-
Shao, Xiaoqi, Huang, Bingying, Tan, Huiling, Wang, Ruonan, Huang, Xueying, Diao, Hongtao, Cheng, Jiawen, Sun, Mengxian, Wang, Dongwei, Wu, Kaili, Yan, Meiling, Rong, Xianglu, Zhang, Yue, and Guo, Jiao
- Subjects
ECHOCARDIOGRAPHY ,REVERSE transcriptase polymerase chain reaction ,MYOCARDIUM ,HEART cells ,HERBAL medicine ,DIABETIC cardiomyopathy ,MYOCARDIAL ischemia ,ANIMAL experimentation ,WESTERN immunoblotting ,MYOCARDIAL infarction ,HYPERLIPIDEMIA ,METABOLIC disorders ,GENE expression ,CHINESE medicine ,MICE ,CELL death ,HEART failure ,PHYSIOLOGIC salines ,THERAPEUTICS - Abstract
Background. Fu Fang Zhen Zhu Tiao Zhi (FTZ) is a traditional Chinese herbal prescription widely used to treat dyslipidemia, metabolic diseases, and diabetic coronary disorders. Cardiomyocyte death and loss of regenerative ability cause cardiac dysfunction and heart failure. FTZ can effectively treat diabetic cardiomyopathy and macrovascular diseases; however, the mechanism behind the phenomenon is still unclear. Here, we determined the mechanism of action of FTZ in treating myocardial infarction. Methods. Male C57BL/6 mice were treated with 2.4 or 1.2 g/kg FTZ, or administered saline by oral gavage daily for four weeks, and a 24-hour ligation was administered to the artery. Echocardiography was used to evaluate cardiac function. Hematoxylin and eosin and Evans blue/triphenyltetrazolium chloride staining were carried out by staining the cardiac tissue, used to evaluate cardiac function and infarct size. Using western blotting and reverse transcriptase-polymerase chain reaction, we determined the relative levels of NOD-like receptor protein (NLRP) 3, ASC, cleaved caspase-l (C-Caspase-1), GSDMD, and GSDMD-N. TUNEL, immunohistochemical, and immunofluorescence staining were used to determine cell death and NLRP3 expression. An enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of interleukin (IL)-1β and IL-18. Results. FTZ reduced ischemia-induced cardiomyocyte cell death in vivo and H
2 O2 -induced cell death in vitro by maintaining cardiac architecture and restoring cardiac function. FTZ decreased the NLRP3 expression and inhibited pyroptosis-correlated genes, including NLRP3, ASC, GSDMD, C-Caspase-1, and GSDMD-N. NLRP3 overexpression impaired the efficacy of FTZ by inducing pyroptosis. Conclusion. FTZ could preserve cardiac function resulting from ischemic insult by inhibiting pyroptosis, which was partially reversed by NLRP3 overexpression, indicating that NLRP3 could be a potential target of FTZ in treating myocardial infarction. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis.
- Author
-
Lan, Tian, Xu, Tonghao, Fu, Yanfang, Jiang, Shuo, Liang, Xiaolin, Yu, Ze, Pan, Linyu, Rong, Xianglu, and Guo, Jiao
- Subjects
NON-alcoholic fatty liver disease ,CHINESE medicine ,INTESTINES ,MICE ,HEMATOXYLIN & eosin staining - Abstract
Nonalcoholic steatohepatitis (NASH) has become a major cause of liver transplantation and liver-associated death. Targeting the gut–liver axis is a potential therapy for NASH. The Fufang Zhenzhu Tiaozhi (FTZ) capsule, a traditional Chinese medicine commonly used in clinical practice, has recently emerged as a promising drug candidate for metabolic diseases such as NASH. The present study aimed to investigate whether FTZ exerts an anti-NASH effect by targeting the gut–liver axis. Mice were fed with a high-fat diet (HFD) for 20 weeks to induce NASH. HFD-fed mice were daily intragastrically administrated with FTZ at 10 weeks after tbe initiation of HFD feeding. The mRNA levels of genes associated with the intestinal tight junction, lipid metabolism, and inflammation were determined by the q-PCR assay. Hepatic pathology was evaluated by H&E staining. The gut microbiota was analyzed by 16S rRNA gene sequencing. FTZ attenuated HFD-induced obesity, insulin resistance, and hepatic steatosis in mice. FTZ treatment decreased the elevated levels of serum aminotransferases and liver triglyceride in NASH mice. Furthermore, FTZ treatment reduced hepatic inflammatory cell infiltration and fibrosis in mice. In addition, FTZ attenuated the intestinal inflammatory response and improved intestinal barrier function. Mechanistically, FTZ-treated mice showed a different gut microbiota composition compared with that in HFD-fed mice. Finally, we identified eight differential metabolites that may contribute to the improvement of NASH with FTZ treatment. In summary, FTZ ameliorates NASH by inhibiting gut inflammation, improving intestinal barrier function, and modulating intestinal microbiota composition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. The Traditional Chinese Medicine Formula FTZ Protects against Cardiac Fibrosis by Suppressing the TGFβ1-Smad2/3 Pathway.
- Author
-
Zhang, Yue, Wang, Dongwei, Wu, Kaili, Shao, Xiaoqi, Diao, Hongtao, Wang, Zhiying, Sun, Mengxian, Huang, Xueying, Li, Yun, Tang, Xinyuan, Yan, Meiling, and Guo, Jiao
- Subjects
TRANSFORMING growth factors-beta ,WOUND healing ,HERBAL medicine ,FIBROBLASTS ,ANIMAL experimentation ,CARDIOVASCULAR diseases ,FIBROSIS ,DOPPLER echocardiography ,TREATMENT effectiveness ,CELL proliferation ,MEDICAL prescriptions ,POLYMERASE chain reaction ,CHINESE medicine ,MICE - Abstract
Background. Fu fang Zhen Zhu Tiao Zhi (FTZ) is a patented preparation of Chinese herbal medicine that has been used as a natural medicine to treat several chronic diseases including cardiovascular disease. However, its effects on cardiac fibrosis remain unclear. Therefore, this study was designed to investigate the effects and potential mechanisms of FTZ in treating cardiac fibrosis. Methods. FTZ was administered to mice by oral gavage daily at a dosage of 1.2 g/kg or 2.4 g/kg of body weight for 7 weeks after a transverse aorta constriction (TAC) surgery. Doppler echocardiography, hematoxylin and eosin staining, and Masson's trichrome staining were used to assess the effect of FTZ on the cardiac structure and function of mice that had undergone TAC. EdU and wound-healing assays were performed to measure the proliferative and migratory abilities of cardiac fibroblasts. Western blotting and qRT-PCR were used to determine the expression of TGFβ1, Col1A2, Col3, and α-SMA proteins and mRNA levels. Results. FTZ treatment reduced collagen synthesis, attenuated cardiac fibrosis, and improved cardiac function in mice subjected to TAC. Moreover, FTZ treatment prevented the proliferation and migration of cardiac fibroblasts and reduced Ang-II-induced collagen synthesis. Furthermore, FTZ downregulated the expression of TGFβ1, p-smad2, and p-smad3 and inhibited the TGFβ1-Smad2/3 pathway in the setting of cardiac fibrosis. Conclusion. FTZ alleviated the proliferation and migration of cardiac fibroblasts and suppressed collagen synthesis via the TGFβ1-Smad2/3 pathway during the progression of cardiac fibrosis. These findings indicated the therapeutic potential of FTZ in treating cardiac fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Long-Term Effect of Zhenzhu Tiaozhi Capsule (FTZ) on Hyperlipidemia: 2-Year Results from a Retrospective Study Using Electronic Medical Records.
- Author
-
Huang, Xiaoqiang, Zhan, Huixia, Yang, Jin, Peng, Liufen, Piao, Shenghua, Wang, Lexun, Lan, Tian, Rong, Xianglu, and Guo, Jiao
- Subjects
DRUG therapy for hyperlipidemia ,TRIGLYCERIDES ,DRUG efficacy ,HERBAL medicine ,MEDICAL databases ,INFORMATION storage & retrieval systems ,ANTILIPEMIC agents ,PHARMACEUTICAL encapsulation ,RETROSPECTIVE studies ,LOW density lipoproteins ,MEDICAL laboratories ,ELECTRONIC health records ,HOSPITAL information systems ,CHINESE medicine ,LIPIDS ,CHOLESTEROL ,DRUG administration ,DRUG dosage - Abstract
The objective of this work was to study the lipid profile (LDL, TC, TG, and HDL) over 2 years in patients with hyperlipidemia in a real-world clinical setting and to describe the dynamical trajectory of lipid profile change in response to lipid-lowering treatment (Zhenzhu Tiaozhi capsule (FTZ) vs. general lipid-lowering treatment, i.e., statins, fibrates, and Xuezhikang). We conducted a retrospective study that included people aged ≥18 years with hyperlipidemia that initiated lipid-lowering treatment between January 2010 and December 2020. Demographic, diagnosis, and laboratory data were retrieved from hospital's electronic medical records, including hospital information system (HIS) and the laboratory information system (LIS). Follow-up trajectories of lipid profile were plotted in a generalized additive mixed model (GAMM) with smooth splines. A total of 839 patients with hyperlipidemia were included. Within 2 years, LDL, TC, and TG descended steadily and gently in the FTZ group (N = 99), while the general lipid-lowering treatment (N = 740) shortly improved LDL, TC, and TG before 11 weeks and was no longer present around 30 weeks. After 30 weeks, the trajectory of LDL, TC, and TG fluctuated up and down. Also, for HDL, a similar trajectory was observed before 40 weeks between 2 groups, but the FTZ group showed an increasing trend after 40 weeks, while a similar trend was not seen in the general lipid-lowering group. In this study, FTZ was shown to have similar long-term effectiveness as an alternative lipid-lowering treatment to the general lipid-lowering treatment. The findings of this study provide observational evidence for further studies of FTZ, but more prospective studies are needed to determine the impacts of FTZ on lipid profile. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. FTZ Ameliorates Diabetic Cardiomyopathy by Inhibiting Inflammation and Cardiac Fibrosis in the Streptozotocin-Induced Model.
- Author
-
Wang, Lexun, Wu, Huijuan, Deng, Yanyue, Zhang, Shengxi, Wei, Quxing, Yang, Qianqian, Piao, Shenghua, Bei, Weijian, Rong, Xianglu, and Guo, Jiao
- Subjects
DRUG efficacy ,BIOLOGICAL models ,BIOMARKERS ,INTERLEUKINS ,HERBAL medicine ,DIABETIC cardiomyopathy ,INFLAMMATION ,ANIMAL experimentation ,WESTERN immunoblotting ,SERUM ,FIBROSIS ,CELLULAR signal transduction ,MESSENGER RNA ,CHEMOKINES ,CHINESE medicine ,MICE ,PHARMACOKINETICS - Abstract
Background. The pathogenesis and clinical features of diabetic cardiomyopathy (DCM) have been well studied in the past decade; however, effective approaches to prevent and treat this disease are limited. Fufang Zhenzhu Tiaozhi (FTZ) formula, a traditional Chinese prescription, is habitually used to treat dyslipidemia and diabetes. Recently, several studies have reported the therapeutic effects of FTZ on cardiovascular diseases. However, the effects of FTZ on DCM have not yet been fully elucidated. This study investigated the effects of FTZ on DCM and determined the mechanisms underlying its efficacy. Methods. Diabetes was induced in mice by intraperitoneal injection of streptozotocin; the mice were randomly divided into a control group (Con), diabetes group (DCM), and diabetes-treated with FTZ (DCM + FTZ). Myocardial structural alterations, fibrosis biomarkers, and inflammation were observed. Besides, the potential targets and their related signaling pathways were analyzed using network pharmacology and further verified by Western blot. Results. Diabetic mice showed significant body weight loss, hyperglycemia, and excessive collagen content in the cardiac tissue, while serum and myocardial inflammatory factors significantly increased. Nerveless, treatment with FTZ for 1 month significantly improved body weight, attenuated hyperglycemia, and alleviated diabetes-associated myocardial structure and function abnormalities. Furthermore, the serum levels of interleukin 12 (IL-12) and chemokine (C–C motif) ligand 2 (CCL2) as well as the mRNA levels of cardiac IL-12, IL-6, and C–C motif chemokine receptor 2 (Ccr2) reduced after FTZ treatment. Additionally, a total of 67 active compounds and 76 potential targets related to DCM were analyzed. Pathway and functional enrichment analyses showed that FTZ mainly regulates inflammation-related pathways, including MAPK and PI3K-AKT signaling pathways. Further investigation revealed that the activities of STAT3, AKT, and ERK were augmented in diabetic hearts but decreased in FTZ-treated cardiac tissues. Conclusion. Our results suggest that FTZ exhibits therapeutic properties against DCM by ameliorating hyperglycemia-induced inflammation and fibrosis via at least partial inhibition of AKT, ERK, and STAT3 signaling pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
- Author
-
Wang, Lexun, Xiang, Lei, Piao, Shenghua, Gong, Xiao, Zhou, Wanxing, Feng, Weixun, Li, Huilin, Li, Leyu, Wei, Aisheng, Zhu, Qing, Rong, Xianglu, and Guo, Jiao
- Subjects
CORONARY disease ,CHINESE medicine ,RESEARCH protocols ,TYPE 2 diabetes ,SAFETY ,ACUTE coronary syndrome - Abstract
Background: Diabetic coronary heart disease (DCHD), the main macrovascular complication of type 2 diabetes mellitus (T2DM), is greatly harmful to T2DM patients. Traditional Chinese medicine (TCM) is an alternative and effective therapy to delay the development of macrovascular diseases, but the existing evidence of its efficacy and safety is insufficient. The aim of this multicenter, randomized, double-blind, placebo-controlled trial is to evaluate the efficacy and safety of Chinese Medicine Fufang Zhenzhu Tiaozhi capsule (FTZ) in treating DCHD. Patients and Methods: This study includes a 2-week run-in, 52-week treatment, and 52-week post-treatment follow-up. A total of 160 participants will be recruited and randomized into two groups. The treatment group will receive FTZ and basic treatment, while the control group will receive the placebo and basic treatment. The primary outcome is the combined outcome including the major adverse cardiovascular events, coronary restenosis, and unplanned revascularization. The combined secondary outcomes include all-cause mortality, acute coronary syndrome, ischemic stroke, heart failure, unplanned re-hospitalization mainly caused by acute complications of diabetes, other thromboembolic events, and TCM symptom indicators. The safety outcomes and adverse events will also be evaluated in this trial. Discussion: This trial evaluates the clinical effectiveness and safety of FTZ in patients with DCHD. The results are important to further explore the effectiveness of the comprehensive strategy "Tiao Gan Qi Shu Hua Zhuo" (modulating Gan, trigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness) in the prevention and control of glucolipid metabolic disorders (GLMD) including DCHD and T2DM. On the other hand, this study is the first trial of FTZ to observe cardiovascular outcomes through long-term follow-up after treatment of DCHD, which is of great value. Trial Registration: This trial was registered in the Chinese Clinical Trial Registry on April 07, 2019 (No. ChiCTR1900022345). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Finger Citron Extract Ameliorates Glycolipid Metabolism and Inflammation by Regulating GLP-1 Secretion via TGR5 Receptors in Obese Rats.
- Author
-
Yang, Yujiao, Tian, Aofei, Wu, Zhen, Wei, Yao, Hu, Xuguang, and Guo, Jiao
- Subjects
LIPID metabolism ,OBESITY treatment ,HERBAL medicine ,BODY weight ,INFLAMMATION ,GLUCAGON-like peptide 1 ,ANIMAL experimentation ,LIVER ,FLUIDS ,RATS ,ENZYME-linked immunosorbent assay ,WAIST circumference ,DESCRIPTIVE statistics ,POLYMERASE chain reaction ,CITRUS ,CHINESE medicine - Abstract
Finger citron (FC) is one of many traditional Chinese herbs that have been used to treat obesity. The aim of this study was to elucidate the pharmacological effects and mechanisms of FC on obese rats. Rats were fed with a high-fat diet as a model of obesity and treated with FC at three different dosages for 6 weeks. Pathology in liver tissue was observed. Glucose levels, lipids levels, and inflammatory indicators in serum were evaluated by enzyme‐linked immunosorbent assay. Furthermore, the expression of G protein-coupled receptor 5 (TGR5) pathway genes in rat colon tissue was detected by reverse transcription-polymerase chain reaction analysis (RT-PCR). Our result revealed that FC alleviates obesity by reducing body weight (BW) and waist circumference, managing inflammation and improving glycolipid metabolism, liver function, and liver lipid peroxidation in vivo. In addition, the mechanism of FC on obesity is possibly the stimulation of glucagon-like peptide-1 (GLP-1) secretion by activating the TGR5 pathway in intestinal endocrine cells. Our studies highlight the obesity reduction effects of FC and one of the mechanisms may be the activation of the TGR5 pathway in intestinal endocrine cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Tian-Huang Formula, a Traditional Chinese Medicinal Prescription, Improves Hepatosteatosis and Glucose Intolerance Targeting AKT-SREBP Nexus in Diet-Induced Obese Rats.
- Author
-
Li, Kun-Ping, Yu, Yang, Yuan, Min, Zhang, Chu-Mei, Rong, Xiang-Lu, Turnbull, Jeremy E., and Guo, Jiao
- Subjects
OBESITY complications ,BLOOD sugar analysis ,GLUCOSE intolerance ,PROTEIN kinases ,TRIGLYCERIDES ,BODY weight ,FATTY liver ,ANIMAL experimentation ,METABOLOMICS ,WESTERN immunoblotting ,PHOSPHOTRANSFERASES ,DIET ,LOW density lipoproteins ,CELL receptors ,RATS ,CYTOCHEMISTRY ,INSULIN ,POLYMERASE chain reaction ,MOLECULAR structure ,CHINESE medicine ,CARRIER proteins ,ASPARTATE aminotransferase ,INSULIN resistance ,BLOOD - Abstract
The progressive increase of metabolic diseases underscores the necessity for developing effective therapies. Although we found Tian-Huang formula (THF) could alleviate metabolic disorders, the underlying mechanism remains to be fully understood. In the present study, firstly, male Sprague-Dawley rats were fed with high-fat diet plus high-fructose drink (HFF, the diet is about 60% of calories from fat and the drink is 12.5% fructose solution) for 14 weeks to induce hepatosteatosis and glucose intolerance and then treated with THF (200 mg/kg) for 4 weeks. Then, metabolomics analysis was performed with rat liver samples and following the clues illustrated by Ingenuity Pathway Analysis (IPA) with the metabolomics discoveries, RT-qPCR and Western blotting were carried out to validate the putative pathways. Our results showed that THF treatment reduced the body weight from 735.1 ± 81.29 to 616.3 ± 52.81 g and plasma triglyceride from 1.5 ± 0.42 to 0.88 ± 0.33 mmol/L; meanwhile, histological examinations of hepatic tissue and epididymis adipose tissue showed obvious alleviation. Compared with the HFF group, the fasting serum insulin and blood glucose level of the THF group were improved from 20.77 ± 6.58 to 9.65 ± 5.48 mIU/L and from 8.96 ± 0.56 to 7.66 ± 1.25 mmol/L, respectively, so did the serum aspartate aminotransferase, insulin resistance index, and oral glucose tolerance (p = 0.0019, 0.0053, and 0.0066, respectively). Furthermore, based on a list of 32 key differential endogenous metabolites, the molecular networks generated by IPA suggested that THF alleviated glucose intolerance and hepatosteatosis by activating phosphatidylinositol-3 kinase (PI3K) and low-density lipoprotein receptor (LDL-R) involved pathways. RT-qPCR and Western blotting results confirmed that THF alleviated hepatic steatosis and glucose intolerance partly through protein kinase B- (AKT-) sterol regulatory element-binding protein (SREBP) nexus. Our findings shed light on molecular mechanisms of THF on alleviating metabolic diseases and provided further evidence for developing its therapeutic potential. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and Prospective.
- Author
-
Luo, Ting-ting, Lu, Yuan, Yan, Shi-kai, Xiao, Xue, Rong, Xiang-lu, and Guo, Jiao
- Subjects
DRUG design ,HERBAL medicine ,MEDICAL research ,CHINESE medicine ,METABOLISM ,MOLECULAR biology ,PHARMACOLOGY ,PHYTOCHEMICALS - Abstract
Chinese medicine (CM) is usually prescribed as CM formula to treat disease. The lack of effective research approach makes it difficult to elucidate the molecular mechanisms of CM formula owing to its complicated chemical compounds. Network pharmacology is increasingly applied in CM formula research in recent years, which is identified suitable for the study of CM formula. In this review, we summarized the methodology of network pharmacology, including network construction, network analysis and network verification. The aim of constructing a network is to achieve the interaction between the bioactive compounds and targets and the interaction between various targets, and then find out and validate the key nodes via network analysis and network verification. Besides, we reviewed the application in CM formula research, mainly including targets discovery, bioactive compounds screening, toxicity evaluation, mechanism research and quality control research. Finally, we proposed prospective in the future and limitations of network pharmacology, expecting to provide new strategy and thinking on study for CM formula. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Chinese Medicine FTZ Recipe Protects against High-Glucose-Induced Beta Cell Injury through Alleviating Oxidative Stress.
- Author
-
Bei, Weijian, Wang, Yujiao, Chen, Jianmei, Zhang, Jingjing, Wang, Lexun, Gu, Zhanhui, Hu, Yinming, Huang, Yijian, Xu, Wei, Lei, Zili, Cai, Jinyan, and Guo, Jiao
- Subjects
REACTIVE oxygen species ,ANIMAL experimentation ,BIOLOGICAL models ,PHARMACEUTICAL encapsulation ,CATALASE ,HERBAL medicine ,HYPERGLYCEMIA ,ISLANDS of Langerhans ,CHINESE medicine ,RATS ,SUPEROXIDE dismutase ,MALONDIALDEHYDE ,OXIDATIVE stress ,CASPASES ,PHARMACODYNAMICS - Abstract
Objective. To investigate the effect of FTZ on high-glucose-induced oxidative stress and underlying mechanisms. Methods. We used a β cell dysfunction and diabetes model that was induced in rats fed a high-fat high-sugar diet (HFHSD) for 6 weeks and injected once with 35 mg/kg streptozocin (STZ). Then, 3 and 6 g/kg of FTZ were administered by gavage for 8 weeks. In addition, an ex vivo model of oxidative stress was induced by stimulating INS-1 cells with 25 mmol/L glucose for 48 h. Result. The levels of fasting blood glucose (FBG) in diabetic model rats were obviously higher than those in the normal group; furthermore with reduced levels of β cells, catalase (CAT), superoxide dismutase (SOD), and Bcl-2 increased lipid peroxide malondialdehyde (MDA) and caspase-3 in the pancreatic tissue of the diabetic model rats. Afterward, the cells were incubated with FTZ-containing serum and edaravone. The 25 mmol/L glucose-induced SOD reduction increased MDA and intracellular ROS. The protein expression level of Mn-SOD and CAT in the model group decreased significantly compared with that in the control group. Conclusion. FTZ treatment significantly improved the alteration in the level of SOD, CAT, Bcl-2, caspase-3, and MDA coupled with β cell dysfunction in diabetic rats. Oxidative stress in INS-1 cells was closely associated with a higher rate of apoptosis, increased production of ROS and MDA, enhanced Bax expression, and caspase-3, -9 activities and markedly decreased protein expression of Mn-SOD and CAT. FTZ-containing serum incubation notably reversed the high-glucose-evoked increase in cell apoptosis, production of ROS and MDA, and Bax protein levels. Furthermore, FTZ stimulation upregulated the expression levels of several genes, including Mn-SOD, CAT, and Bcl-2/Bcl-xl. In addition, FTZ decreased the intracellular activity of caspase-3, -9 in INS-1 cells. FTZ protected β-cells from oxidative stress induced by high glucose in vivo and in vitro. The beneficial effect of FTZ was closely associated with a decrease in the activity of caspase-3, -9 and intracellular production of ROS, MDA, and Bax coupled with an increase in the expression of Mn-SOD, CAT, and Bcl-2/Bcl-xl. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis.
- Author
-
Sun, Xu, Zhang, Xing, Nian, Jia-Yun, Guo, Jiao, Yin, Yi, Zhang, Gan-Lin, Yu, Ming-Wei, Zhang, Yi, Wang, Xiao-Min, Yang, Guo-Wang, Yang, Lin, Cheng, Pei-Yu, and Li, Jin-Ping
- Subjects
CHINESE medicine ,BREAST tumors ,CANCER chemotherapy ,COMBINED modality therapy ,HERBAL medicine ,META-analysis ,SYSTEMATIC reviews ,TREATMENT effectiveness - Abstract
Chinese herbal medicine (CHM) has been increasingly employed during therapy for breast cancer, but its efficacy remains a matter of debate. This systematic review examined randomized controlled trials to provide a critical evaluation of this treatment. The results demonstrated that the combined use of CHM with chemotherapy may improve the immediate tumor response and reduce chemotherapy-associated adverse events. Our findings highlight the poor quality of Chinese studies, and additional well-designed randomized controlled trials addressing the role of CHM are warranted. The lack of molecular-based evidence for CHM and Zheng has resulted in a limited understanding and acceptance of CHM and traditional Chinese medicine in Western countries. We believe that researchers should immediately explore a CHM-based cure, and CHM should be applied to routine care as soon as conclusive data are available. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats
- Author
-
Guo, Jiao, Bei, Weijian, Hu, Yinming, Tang, Chunping, He, Wei, Liu, Xiaobo, Huang, Lihua, Cao, Yang, Hu, Xuguang, Zhong, Xunlong, and Cao, Le
- Subjects
- *
HYPERCHOLESTEREMIA prevention , *ALTERNATIVE medicine , *ANALYSIS of variance , *ANIMAL experimentation , *BIOLOGICAL assay , *BIOPHYSICS , *CHOLESTEROL , *FECES , *HIGH performance liquid chromatography , *HISTOLOGICAL techniques , *LIVER , *MATHEMATICS , *RESEARCH methodology , *MEDICINAL plants , *BOTANIC medicine , *CHINESE medicine , *POLYMERASE chain reaction , *RATS , *RESEARCH funding , *STATISTICS , *DATA analysis , *STATISTICAL significance , *REVERSE transcriptase polymerase chain reaction - Abstract
Abstract: Ethnopharmacological relevance: Based on a theory of Chinese Medicine, Regulating Gan (liver) to lower lipids that is in brief to regulate the lipid metabolic related factors in the liver will improve serum lipid profile, we have developed Fufang Zhenzhu Tiao Zhi (FTZ) which includes eight herbs that are quality assured. FTZ has been developed with the potential to correct abnormal lipid metabolism. This Chinese herbal medicine has been prescribed for 20years, which has been issued patent and clinically proven for use in the treatment of dyslipidemia. Aim of the study: To investigate the cholesterol-lowering effect and the mode of action of FTZ extract on high lipid diet induced hyperlipidemic rats. Materials and methods: The FTZ was prepared by alcohol and water extraction of eight herbs that have been quality-controlled according to the protocol. The cholesterol-lowering effect of FTZ was evaluated on SD rats fed with high-lipid diet. RT-PCR and western blot were used to analyze the gene expression of cholesterol metabolism-related enzymes including HMG-CoA reductase and cholesterol 7α-hydroxylase (CYP7A1) in the livers of the rats. The activity of HMG-CoA reductase and CYP7A1 were assessed by colorimetrical method and by quantification of the cholesterol metabolite of CYP7A1 using HPLC analysis respectively. Results and conclusions: FTZ significantly decreased the levels of serum total cholesterol (TC), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C), whilst elevated the serum high-density lipoprotein cholesterol (HDL-C) and decreased serum atherogenic index (A.I.) values in high lipid diet induced hyperlipidemic rats. Furthermore, FTZ showed significant antihyperlipidemic effect by at least three pathways in the high lipid diet induced hyperlipidemic rats: (1) upregulating the gene expression and activity of CYP7A1 which promotes the conversion of cholesterol into bile acid; (2) downregulating the gene expression and activity of HMG-CoA reductase to reduce de novo synthesis of cholesterol; (3) increasing the cholesterol excretion from feces. In these three pathways, HMG-CoA reductase and CYP7A1 are two pivotal enzymes in lipid cholesterol metabolism and are expressed mainly in hepatic cells, which support our new TCM treatment strategy: Modulating Liver to Treat Hyperlipemia. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
17. Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits.
- Author
-
Zhang, Rendan, Li, Tudi, Guo, Jiao, Zhao, Yanqun, Liu, Yuhong, Yao, Yusi, and Zeng, Zhihuan
- Subjects
CHINESE medicine ,CORONARY restenosis prevention ,NF-kappa B ,HIGH-fat diet ,LABORATORY rabbits - Abstract
Background: To investigate the effects of a Chinese herbal medicine Fufang-Zhenzhu Tiaozhi Capsule (FTZ) on restenosis and elucidate the mechanism of action. Methods: A restenosis model was established by balloon rubbing the endothelium of the abdominal aorta followed by high fat diet. Rabbits were divided into blank control group, restenosis group, FTZ group (0.66 mg/kg/day), atorvastatin group (5 mg/kg/day) and FTZ + atorvastatin group (n = 8). Vascular stenosis was analyzed by X-ray. Serum levels of chemokines and cytokines interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12 (IL-12), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) were measured by ELISA. The levels of NF-κB, IκB-α, P-IκBα, IKK-α, and P-IKKα/β from injured abdominal arteries were detected by Western blotting. Results: Restenosis was induced successfully via abdominal artery balloon injuries and high fat diet. Restenosis was significantly decreased in FTZ group compared with restenosis group (P < 0.05). FTZ group had markedly reduced serum lipid levels (P < 0.05). In addition, the levels of TNF-α, IL-1, IL-6, IL-8, IL-12, ICAM-1 and MCP-1 decreased by FTZ treatment (P < 0.05). The expression of NF-κB in the atherosclerotic lesions was significantly attenuated in FTZ group (P < 0.05). Conclusion: FTZ could reduce restenosis via reducing NF-κB activity and inflammatory factor expression within the atherosclerotic lesion in a rabbit restenosis model. FTZ may be a new therapeutic agent for restenosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Fufang Zhenzhu Tiaozhi (FTZ) capsule ameliorates diabetic kidney disease in mice via inhibiting the SGLT2/glycolysis pathway.
- Author
-
Lin, Ziyang, Huo, Hongyan, Huang, Minyi, Tao, Jie, Yang, Yiqi, and Guo, Jiao
- Subjects
- *
ENZYME analysis , *KIDNEY physiology , *METABOLIC disorders , *CHINESE medicine , *COMPUTER-assisted molecular modeling , *PROTEINURIA , *GLUCOSE , *HDL cholesterol , *GLYCOLYSIS , *CREATININE , *HERBAL medicine , *DIABETIC nephropathies , *LIPIDS , *GLUCOSE tolerance tests , *HYPOGLYCEMIC agents , *CELLULAR signal transduction , *LDL cholesterol , *BLOOD urea nitrogen , *LACTATE dehydrogenase , *MICE , *IMMUNOHISTOCHEMISTRY , *BLOOD sugar , *DOSE-effect relationship in pharmacology , *GENE expression , *ANIMAL experimentation , *WESTERN immunoblotting , *CHOLESTEROL , *SODIUM-glucose cotransporter 2 inhibitors , *TRIGLYCERIDES , *DIABETES , *THERAPEUTICS , *PHARMACODYNAMICS - Abstract
Fufang Zhenzhu Tiaozhi (FTZ) capsule is a hospital preparation of a patented traditional Chinese medicine compound. FTZ has been clinically used for nearly 13 years in the treatment of diabetes and glycolipid metabolic diseases. With the significant benefits of SGLT2 inhibitor in patients with diabetic kidney disease (DKD), it provides a research avenue to explore the mechanism of FTZ in treating this disease based on glycolysis pathway. To explore the pharmacological characteristics of FTZ in DKD mice and its impact on the glycolysis pathway. We induced a DKD model in C57BL/6 mice by injection of streptozotocin (STZ) combined with long-term high-fat diet. We administered three doses of FTZ for 12 weeks of treatment. Kidney function, blood lipid levels, glucose tolerance, and key glycolytic enzymes were evaluated. Renal pathological changes were observed using HE, MASSON, and PAS staining. The potential targets of the active ingredients of FTZ in the glycolysis pathway were predicted using network pharmacology and molecular docking. Validation was performed using immunohistochemistry and Western blotting. FTZ effectively reduces blood glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, 24 h proteinuria, serum creatinine, blood urea nitrogen, and increases urinary glucose levels. Glucose tolerance and renal pathological changes were significantly improved by FTZ treatment. Pinusolidic acid, a component of FTZ, shows good binding affinity with three active pockets of SGLT2. WB and immunohistochemistry revealed that FTZ significantly inhibits the expression of SGLT2 and its glycolytic related proteins (GLUT2/PKM2/HK2). Hexokinase, pyruvate kinase, and lactate dehydrogenase in the kidney were also significantly inhibited by FTZ in a dose-dependent manner. FTZ may alleviate the progression of DKD by inhibiting the activation of the SGLT2/glycolytic pathway. Our study provides new insights into the clinical application of FTZ in DKD. FTZ reduces blood glucose and lipid levels, improves kidney function and glucose tolerance by inhibiting SGLT2 and the glycolytic pathway, potentially helping to alleviate diabetic kidney disease (DKD). One of the components of FTZ, pinusolidic acid, has good binding affinity with three active sites of SGLT2. FTZ significantly inhibits SGLT2 and its related glycolysis protein expression, and dose-dependently inhibits hexokinase, pyruvate kinase, and lactate dehydrogenase in the kidneys. The study concludes that FTZ may help to alleviate the progression of DKD by inhibiting the SGLT2/glycolysis pathway, providing new insights into the clinical application of FTZ in DKD. Abbreviation: SGLT2, Sodium-glucose co-transporter 2; FTZ, Fufang Zhenzhu Tiaozhi capsule; DKD, Diabetic kidney disease; STZ, Streptozotocin; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TC, Total cholesterol; TG, Triglyceride; UACR, Urinary albumin creatinine ratio; Src, Serum creatinine; BUN, Blood urea nitrogen; PK, Pyruvate kinase; HK, Hexokinase; HK2, Hexokinase II; PKM2, pyruvate kinase M2; GLUT2, Glucose transporter-2. [Display omitted] • FTZ promotes urinary glucose excretion and improves abnormal renal glycolysis. • Bioinformatics analysis has revealed the potential connection between the active components of FTZ and SGLT2. • FTZ ameliorates renal injury in mice with diabetic kidney disease via the SGLT2/glycolysis pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Fufang Zhenzhu Tiaozhi (FTZ) suppression of macrophage pyroptosis: Key to stabilizing rupture-prone plaques.
- Author
-
Shao, Xiaoqi, Zeng, Wenru, Wang, Qing, Liu, Suping, Guo, Qiaoling, Luo, Duosheng, Luo, Qingmao, Wang, Dongwei, Wang, Lexun, Zhang, Yue, Diao, Hongtao, Piao, Shenghua, Yan, Meiling, and Guo, Jiao
- Subjects
- *
HERBAL medicine , *ANIMAL experimentation , *IMMUNOHISTOCHEMISTRY , *APOPTOSIS , *MACROPHAGES , *GENE expression , *SEVERITY of illness index , *CORONARY artery disease , *DESCRIPTIVE statistics , *ENZYME-linked immunosorbent assay , *MESSENGER RNA , *DATA analysis software , *BIOLOGICAL assay , *CHINESE medicine , *MICE - Abstract
Research on the Chinese herbal formula Fufang Zhenzhu Tiaozhi (FTZ) has demonstrated its effectiveness in treating hyperlipidemia and glycolipid metabolic disorders. Additionally, FTZ has shown inhibitory effects on oxidative stress, regulation of lipid metabolism, and reduction of inflammation in these conditions. However, the precise mechanisms through which FTZ modulates macrophage function in atherosclerosis remain incompletely understood. Therefore, this study aims to investigate whether FTZ can effectively stabilize rupture-prone plaques by suppressing macrophage pyroptosis and impeding the development of M1 macrophage polarization in ApoE−/− mice. To assess the impact of FTZ on macrophage function and atherosclerosis in ApoE−/− mice, we orally administered FTZ at a dosage of 1.2 g/kg body weight daily for 14 weeks. Levels of interleukin-18 and interleukin-1β were quantified using ELISA kits to gauge FTZ's influence on inflammation. Total cholesterol content was measured with a Cholesterol Assay Kit to evaluate FTZ's effect on lipid metabolism. Aortic tissues were stained with Oil Red O, and immunohistochemistry techniques were applied to assess atherosclerotic lesions and plaque stability. To evaluate the effects of FTZ on macrophage pyroptosis and oxidative damage, immunofluorescence staining was utilized. Additionally, we conducted an analysis of protein and mRNA expression levels of NLRP3 inflammasome-related genes and macrophage polarization-related genes using RT-PCR and western blotting techniques. This study illustrates the potential therapeutic effectiveness of FTZ in mitigating the severity of atherosclerosis and improving serum lipid profiles by inhibiting inflammation. The observed enhancements in atherosclerosis severity and inflammation can be attributed to the suppression of NLRP3 inflammasome activity and M1 polarization by FTZ. The current findings indicate that FTZ provides protection against atherosclerosis, positioning it as a promising candidate for novel therapies targeting atherosclerosis and related cardiovascular diseases. [Display omitted] • NLRP3 emerges as a potential target for FTZ in combating atherosclerosis. • FTZ crucially regulates the polarization of M1 macrophages and stabilizes atherosclerotic plaques in ApoE−/− mice. • FTZ curtails inflammation by blocking mitochondrial oxidative injuries and macrophage pyroptosis in macrophages. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway.
- Author
-
Lan, Tian, Chen, Bo, Hu, Xianzhe, Cao, Jiafan, Chen, Shiyun, Ding, Xin, Li, Shengwen, Fu, Yanfang, Liu, Huanle, Luo, Duosheng, Rong, Xianglu, and Guo, Jiao
- Subjects
- *
LIVER disease prevention , *INFLAMMATION prevention , *DRUG efficacy , *TRIGLYCERIDES , *HERBAL medicine , *COMBINATION drug therapy , *STAINS & staining (Microscopy) , *SEQUENCE analysis , *ANIMAL experimentation , *WESTERN immunoblotting , *IMMUNOHISTOCHEMISTRY , *FIBROSIS , *CIRRHOSIS of the liver , *RNA , *MACROPHAGES , *TREATMENT effectiveness , *HYDROCARBONS , *COMPARATIVE studies , *CELLULAR signal transduction , *FLUORESCENT antibody technique , *CHINESE medicine , *MICE , *ALANINE aminotransferase , *ASPARTATE aminotransferase , *THERAPEUTICS , *EVALUATION - Abstract
In the progression of chronic liver diseases, liver fibrosis is a reversible pathophysiologic event for liver diseases prognosis and risk of cirrhosis. Liver injury factors of different etiologies mediate this process. There is still a lack of effective medications for treating liver fibrosis. Additionally, the ameliorative effects of traditional herbs on liver fibrosis have been commonly reported. Tianhuang formula (THF) is a drug combination consisting of 2 traditional Chinese herbs, which has been showing significant improvement in metabolic liver diseases. However, the hepatoprotective effect and mechanism of THF in ameliorating liver fibrosis are still unclear. This study aimed to investigate the effects of THF on carbon tetrachloride (CCl 4)-induced and methionine-choline-deficient (MCD) diet-induced liver fibrosis model and to reveal the potential mechanisms. It can provide experimental evidence for THF as a therapeutic candidate for liver fibrosis. In this study, CCl 4 -induced mice were treated with THF (80 mg/kg, 160 mg/kg) or Fuzheng Huayu (FZHY) capsules (4.8 g/kg) for 6 weeks. MCD-induced mice received the same doses of THF or FZHY for 4 weeks. FZHY is used as a comparative study in these two models. Following that, using kit reagents detected changes in relevant serum and liver biochemical indicators. Histological changes in mouse liver were measured by staining of H&E and Sirius Red. The markers expression of liver fibrosis and inflammation were detected using qRT-PCR, western blotting and immunohistochemical staining analysis. The potential regulatory mechanism of THF to ameliorate liver fibrosis was performed by RNA-sequencing analysis. Finally, the analysis results were verified by immunofluorescence co-staining, qRT-PCR and western blotting. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatic triglyceride (TG) levels in CCl 4 and MCD-induced liver fibrosis mice were significantly improved after THF treatment. Meanwhile, the expression of fibrosis and inflammation markers were significantly suppressed. Furthermore, THF downregulated the expression of the macrophage marker CD68. According to RNA-sequencing analysis, we found the CCL2-CCR2 axis and MAPK/NF-κB as the potential signaling pathway for THF against liver fibrosis. This study revealed that THF ameliorated liver injury, inflammation and fibrotic process by inhibiting CCL2-CCR2 axis and its downstream MAPK/NF-κB signaling pathway. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Fufang Zhenzhu Tiaozhi (FTZ) capsule ameliorates diabetes-accelerated atherosclerosis via suppressing YTHDF2-mediated m6A modification of SIRT3 mRNA.
- Author
-
Zhang, Yue, Wang, Ruonan, Tan, Huiling, Wu, Kaili, Hu, Yaju, Diao, Hongtao, Wang, Dongwei, Tang, Xinyuan, Leng, Mingyang, Li, Xu, Cai, Zhenlu, Luo, Duosheng, Shao, Xiaoqi, Yan, Meiling, Chen, Yingyu, Rong, Xianglu, and Guo, Jiao
- Subjects
- *
DIABETES complications , *BIOLOGICAL models , *REVERSE transcriptase polymerase chain reaction , *ENDOTHELIAL cells , *HERBAL medicine , *CAROTID intima-media thickness , *STAINS & staining (Microscopy) , *ANIMAL experimentation , *WESTERN immunoblotting , *APOPTOSIS , *DIABETES , *AMINOGLYCOSIDES , *BLOOD sugar , *ATHEROSCLEROSIS , *TREATMENT effectiveness , *OXIDATIVE stress , *MESSENGER RNA , *DOPPLER ultrasonography , *REACTIVE oxygen species , *CHINESE medicine , *MICE , *LIPIDS , *THERAPEUTICS - Abstract
Fufang Zhenzhu TiaoZhi (FTZ), a Chinese medicinal decoction, has continuously been used to treat metabolic syndrome. Atherosclerosis is the main pathological basis of cardiovascular disease. The N6 methyladenosine (m6A) modification is a highly dynamic and reversible process involving a variety of important biological processes. Here, we investigated the therapeutic effects and mechanism of FTZ in diabetes-accelerated atherosclerosis. Doppler ultrasonography was used to examine the carotid intima-media thickness and plaque area in diabetic atherosclerosis patients. HFD mice were injected with streptozotocin to induce diabetes. HE and Oil red O staining were used to assess the effect of FTZ on lipid deposition. HUVECs were induced with HG/ox-LDL as a model of diabetic atherosclerosis. Furthermore, application of m6A methylation level kit, qRT-PCR, Western blot, tunel staining, reactive oxygen species staining and mPTP staining were performed to analyze the detailed mechanism. Clinical trials of FTZ have shown obvious effect of lowering blood glucose and blood lipids. These effects were reversed after FTZ intervention. Compared with the control, lipid deposition decreased significantly after FTZ administration. FTZ reduced endothelial cell apoptosis. At the same time, we found that FTZ reversed the increase of methylation reader YTHDF2 caused by ox-LDL treatment. Subsequently, we discovered that YTHDF2 degraded SIRT3 mRNA, leading to endothelial cell apoptosis and oxidative stress. FTZ attenuated diabetes-accelerated atherosclerosis by decreasing blood glucose and serum lipids levels, and increased endothelial cell antioxidant capacity, inhibited endothelial cell apoptosis via inhibiting YTHDF2-mediated m6A modification of SIRT3 mRNA, which reduced mRNA degradation. [Display omitted] • FTZ plays a significant inhibitory role in diabetes-accelerated atherosclerosis via YTHDF2-dependent m6A manner. • FTZ mediates m6A modification via regulating YTHDF2. • SIRT3 is one of the underlying targets for the therapeutic effect of FTZ on diabetes-accelerated atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. FTZ promotes islet β-cell regeneration in T1DM mice via the regulation of nuclear proliferation factors.
- Author
-
Zhong, Qin, Yin, Jianying, Wang, Ke, Chen, Xu, Wang, Hong, Hu, Xuguang, Wang, Weixuan, Wang, Lexun, Bei, Weijian, and Guo, Jiao
- Subjects
- *
HERBAL medicine , *STAINS & staining (Microscopy) , *REGENERATION (Biology) , *ANIMAL experimentation , *TYPE 1 diabetes , *ISLANDS of Langerhans , *TREATMENT effectiveness , *CELL proliferation , *DNA-binding proteins , *BENZOPYRANS , *GLUCOSE tolerance tests , *TRANSCRIPTION factors , *CHINESE medicine , *MICE , *EVALUATION - Abstract
Fufang-Zhenzhu-Tiaozhi capsule (FTZ), a Traditional Chinese Medicine (TCM) patent prescription commonly used in clinical practice, has a significant curative effect on hyperglycemia and hyperlipidemia. Previous studies have shown that FTZ can treat diabetes, but the effect of FTZ on β-cell regeneration needs to be further explored in T1DM mice. The aim is to investigate the role of FTZ in promoting β-cell regeneration in T1DM mice, and to further explore its mechanism. C57BL/6 mice were used as control. NOD/LtJ mice were divided into the Model group and FTZ group. Oral glucose tolerance, fasting blood glucose, and fasting insulin level were measured. Immunofluorescence staining was used to detect the level of β-cell regeneration and the composition of α-cells and β-cells in islets. Hematoxylin and eosin staining was used to detect the infiltration degree of inflammatory cells. The apoptosis of islet cells was detected by terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling. Western blotting was used to detect the expression levels of Pancreas/duodenum homeobox protein 1 (PDX-1), V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA), and Neurogenin-3 (NGN3). FTZ could increase insulin levels and reduce the glucose level of T1DM mice and promote β-cell regeneration. FTZ also inhibited the invasion of inflammatory cells and the islet cell apoptosis, and maintained the normal composition of islet cells, thus preserving the quantity and quality of β-cells. Furthermore, FTZ promoting β-cell regeneration was accompanied by increasing the expression of PDX-1, MAFA, and NGN3. FTZ can restore the insulin-secreting function of the impaired pancreatic islet, improve blood glucose level, possibly via the enhancing β cell regeneration via upregulation of PDX-1, MAFA, and NGN3 in T1DM mice, and may be a potential therapeutic drug for T1DM. [Display omitted] • Fufang-Zhenzhu-Tiaozhi capsule (FTZ) can promote β-cell regeneration in type 1 diabetes mellitus model mice. • FTZ might promotes β-cell proliferation by regulating nuclear factors PDX-1, MAFA and NGN3. • It was suggested that FTZ can be used in the treatment of type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi ameliorates diabetic cardiomyopathy by regulating cardiac abnormal lipid metabolism and mitochondrial dynamics in diabetic mice.
- Author
-
Yan, Meiling, Liu, Suping, Zeng, Wenru, Guo, Qiaoling, Mei, Yu, Shao, Xiaoqi, Su, Liyan, Liu, Zhou, Zhang, Yue, Wang, Lexun, Diao, Hongtao, Rong, Xianglu, and Guo, Jiao
- Subjects
- *
DIABETIC cardiomyopathy , *LIPID metabolism , *CARNITINE palmitoyltransferase , *HERBAL medicine , *CHINESE medicine , *MYOCARDIAL reperfusion , *GLYCOLIPIDS - Abstract
Diabetic cardiomyopathy (DCM) is an important complication leading to the death of patients with diabetes, but there is no effective strategy for clinical treatments. Fufang Zhenzhu Tiaozhi (FTZ) is a patent medicine that is a traditional Chinese medicine compound preparation with comprehensive effects for the prevention and treatment of glycolipid metabolic diseases under the guidance of "modulating liver, starting pivot and cleaning turbidity". FTZ was proposed by Professor Guo Jiao and is used for the clinical treatment of hyperlipidemia. This study was designed to explore the regulatory mechanisms of FTZ on heart lipid metabolism dysfunction and mitochondrial dynamics disorder in mice with DCM, and it provides a theoretical basis for the myocardial protective effect of FTZ in diabetes. In this study, we demonstrated that FTZ protected heart function in DCM mice and downregulated the overexpression of free fatty acids (FFAs) uptake-related proteins cluster of differentiation 36 (CD36), fatty acid binding protein 3 (FABP3) and carnitine palmitoyl transferase 1 (CPT1). Moreover, FTZ treatment showed a regulatory effect on mitochondrial dynamics by inhibiting mitochondrial fission and promoting mitochondrial fusion. We also identified in vitro that FTZ could restore lipid metabolism-related proteins, mitochondrial dynamics-related proteins and mitochondrial energy metabolism in PA-treated cardiomyocytes. Our study indicated that FTZ improves the cardiac function of diabetic mice by attenuating the increase in fasting blood glucose levels, inhibiting the decrease in body weight, alleviating disordered lipid metabolism, and restoring mitochondrial dynamics and myocardial apoptosis in diabetic mouse hearts. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment.
- Author
-
Xiong, Pingjie, Zhang, Fan, Liu, Fang, Zhao, Jiayu, Huang, Xiaoqiang, Luo, Duosheng, and Guo, Jiao
- Subjects
- *
METABOLIC disorders , *NON-alcoholic fatty liver disease , *CHINESE medicine , *METABOLIC regulation , *THERAPEUTICS , *EXERCISE therapy - Abstract
The public health issue of glucolipid metabolic disorders (GLMD) has grown significantly, posing a grave threat to human wellness. Its prevalence is rising yearly and tends to affect younger people. Metaflammation is an important mechanism regulating body metabolism. Through a complicated multi-organ crosstalk network involving numerous signaling pathways such as NLRP3/caspase-1/IL-1, NF-B, p38 MAPK, IL-6/STAT3, and PI3K/AKT, it influences systemic metabolic regulation. Numerous inflammatory mediators are essential for preserving metabolic balance, but more research is needed to determine how they contribute to the co-morbidities of numerous metabolic diseases. Whether controlling the inflammatory response can influence the progression of GLMD determines the therapeutic strategy for such diseases. This review thoroughly examines the role of metaflammation in GLMD and combs the research progress of related therapeutic approaches, including inflammatory factor-targeting drugs, traditional Chinese medicine (TCM), and exercise therapy. Multiple metabolic diseases, including diabetes, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease, and others, respond therapeutically to anti-inflammatory therapy on the whole. Moreover, we emphasize the value and open question of anti-inflammatory-based means for treating GLMD. [Display omitted] • Metaflammation has a crucial role in regulating Glucolipid metabolic disorders (GLMD). • Inflammation-associated signaling pathways influence the development of multiple metabolic diseases. • The role of inflammatory mediators in the co-morbidity of multiple metabolic diseases needs to be further investigated. • Anti-inflammatory treatment shows an overall therapeutic effect on multiple metabolic diseases simultaneously. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Fufang-zhenzhu-tiaozhi formula protects islet against injury and promotes β cell regeneration in diabetic mice.
- Author
-
Chen, Xu, Yin, Jianying, Zhong, Qin, Wang, Ke, Zhang, Xiaoyu, Liang, Mingjie, Lin, Quanyou, Wang, Hong, Wang, Weixuan, Wang, Lexun, Hu, Xuguang, Bei, Weijian, and Guo, Jiao
- Subjects
- *
PROTEINS , *HERBAL medicine , *STAINS & staining (Microscopy) , *IN vivo studies , *ANIMAL experimentation , *WESTERN immunoblotting , *CELL physiology , *BLOOD sugar , *TYPE 2 diabetes , *ISLANDS of Langerhans , *WEIGHT loss , *ENZYME-linked immunosorbent assay , *METFORMIN , *TRANSCRIPTION factors , *CHINESE medicine , *MICE , *INSULIN resistance - Abstract
Fufang-zhenzhu-tiaozhi formula (FTZ) is a patented preparation of traditional Chinese medicine that has been used to treat hyperglycemia and hyperlipidemia in the clinic for almost 10 years. Our previous study had demonstrated that FTZ can protect islet β cell injury in vitro. However, the efficacy of FTZ on β cell regeneration in vivo and the involved anti-diabetic mechanism remains unknown. We aim to investigate the effects of FTZ as a good remedy for islet protection and β cell regeneration, and to reveal the underlying mechanism. C57BL/6 mice were fed with high-fat diet for 3 weeks and then intraperitoneally injected with streptozotocin (90 mg/kg/d × 1 d) to establish type 2 diabetes (T2D) models. Mice in each group were divided into three batches that sacrificed after 3, 7 and 28 days of FTZ administration. Body weight, blood glucose, and oral glucose tolerance test were measured at indicated time points. Fasting insulin was determined by enzyme-linked immunosorbent assay (ELISA) kit. Neonatal β cell was assessed by insulin & PCNA double immunofluorescence staining, and the underlying mechanisms related to β cell regeneration were further performed by hematoxylin-eosin staining, insulin & glucagon double immunofluorescence staining and Western blot. FTZ and metformin can significantly help with the symptoms of DM, such as alleviating weight loss, reducing blood glucose, improving the level of insulin in vivo, and relieving insulin resistance, suggesting FTZ and metformin treatment maintained the normal morphological function of islet. Notably, β cell regeneration, which is indicated by insulin and PCNA double-positive cells, was promoted by FTZ, whereas few neonatal β cells were observed in metformin group. Hematoxylin-eosin staining, and its quantification results showed that FTZ effectively prevented the invasion of inflammatory cells into the islets in diabetic mice. Most β cells in the islets of diabetic model mice were devoid, and the islets were almost all α cells, while the diabetic mice administered FTZ could still maintain about half of the β cells in the islet. Furthermore, FTZ upregulated the expression of critical transcription factors during β cell development and maturation (such as PDX-1, MAFA and NGN3) in diabetic mice. FTZ can alleviate diabetes symptoms and promote β cell regeneration in diabetic mice. Moreover, FTZ promotes β cell regeneration by preserving islet (resisting inflammatory cells invading islets), maintaining the number of β cells in islets, and increasing the expression of PDX-1, MAFA and NGN3. [Display omitted] • FTZ alleviates diabetes symptoms, protects islet against injury and promotes β cell regeneration in diabetic mice. • FTZ promotes β cell regeneration by resisting inflammatory and increasing the expression of PDX-1, MAFA and NGN3. • This study identifies a possible therapeutic strategy and provides a potential clinical drug for diabetes in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Chinese medicine Fufang Zhenzhu Tiaozhi capsule ameliorates coronary atherosclerosis in diabetes mellitus-related coronary heart disease minipigs.
- Author
-
Wang, Lexun, Zhang, Dongxing, Zhan, Wenjing, Zeng, Zhihuan, Yin, Jianying, Wang, Ke, Wang, Hong, Song, Lixia, Gu, Zhanhui, Guo, Caijuan, Zhong, Qin, Wang, Weixuan, Rong, Xianglu, Bei, Weijian, and Guo, Jiao
- Subjects
- *
CORONARY disease , *CORONARY artery disease , *CHINESE medicine , *CORONARY artery stenosis , *MYOCARDIAL injury - Abstract
Diabetes mellitus-related coronary heart disease (DM-CHD) is the most common cause of death in diabetic patients. Various studies have shown that Chinese medicine Fufang-Zhenzhu-Tiaozhi capsule (FTZ) has therapeutic effects on cardiovascular diseases. More research is required to determine the mechanism of FTZ protection against coronary atherosclerosis. To investigate the unique mechanism of FTZ in treatment of DM-CHD minipigs with coronary atherosclerosis. High-fat/high-sucrose/high-cholesterol diet combined with streptozotocin and coronary balloon injury were used to induce DM-CHD minipig model, which was then randomly divided into: DM-CHD model, DM-CHD treated with FTZ or positive drug (Metformin + Atorvastatin, M+A). After twenty-two weeks, ultrasonography, electrocardiography, and image detection were employed to detect cardiac functions and assess coronary artery stenosis and plaque. Human umbilical vein endothelial cells (HUVECs) were treated high glucose or/and FTZ. Pigs tissues and treated-cells were collected for further testing. In DM-CHD minipigs, FTZ treatment significantly reduced disordered glycolipid metabolism similar as M+A administration. FTZ and M+A also alleviated coronary stenosis and myocardial injury. In addition, IκB and NF-κB phosphorylation levels, as well as the protein levels of IL-1β, Bax, cleave-Caspase 3, Bcl-2, and α-SMA were dramatically increased in the DM-CHD coronary artery, whereas CD31 and VE-cadherin expressions were decreased. Similar to M+A, FTZ reversed these protein levels in the DM-CHD coronary artery. Furthermore, FTZ ameliorated the damage and high migration activity of HUVECs induced by high glucose. FTZ improves coronary atherosclerosis through modulating inflammation, alleviating apoptosis, and inhibiting EndMT of coronary artery to protects against DM-CHD. [Display omitted] • Coronary atherosclerosis is one of the major pathophysiological mechanisms of DM-CHD. • FTZ attenuates the atherosclerotic plaques in DM-CHD pigs. • Inhibiting coronary inflammation, apoptosis, and EndMT is underline mechanisms of FTZ. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Fufang Zhenzhu Tiaozhi capsule ameliorates hyperuricemic nephropathy by inhibition of PI3K/AKT/NF-κB pathway.
- Author
-
Li, Ming-Hui, Guan, Jin, Chen, Zhe, Mo, Ju-Xian, Wu, Kai-Reng, Hu, Xu-Guang, Lan, Tian, and Guo, Jiao
- Subjects
- *
RNA analysis , *INFLAMMATION prevention , *ACUTE kidney failure prevention , *KIDNEY disease prevention , *HYPERURICEMIA , *PROTEIN kinases , *HERBAL medicine , *KIDNEY function tests , *SEQUENCE analysis , *ANIMAL experimentation , *WESTERN immunoblotting , *FIBROSIS , *CELLULAR signal transduction , *TRANSFERASES , *POLYMERASE chain reaction , *URIC acid , *CHINESE medicine , *MICE , *CREATININE , *PHOSPHORYLATION , *DRUG administration , *DRUG dosage , *DISEASE complications - Abstract
Excessive serum uric acid (SUA) causes hyperuricemic nephropathy (HN), characterized by inflammatory infiltration and tubulointerstitial fibrosis. Most recently, we demonstrated that Fufang Zhenzhu Tiaozhi (FTZ) capsule attenuated diabetic nephropathy through inhibition of renal inflammation and fibrosis. However, whether FTZ ameliorates HN is still unclear. To determine the protective roles and mechanism of FTZ in mouse renal injury and fibrosis under hyperuricemic condition. HN mice, induced by potassium oxonate and hypoxanthine, were administrated with 600 and 1200 mg/kg FTZ (intragastrically) daily for three weeks. SUA levels, renal functions and histological changes were analyzed. Western blotting, quantitative real-time PCR (q-PCR) and RNA sequencing were used to identify the roles and underlying mechanism of FTZ in HN mice. We demonstrated that FTZ treatment mitigated renal injury in mice, as evidenced by the decrease in SUA, serum creatinine (SCr) and cystatin C (Cys C) levels, as well as improved renal histology. FTZ markedly attenuates inflammasome activation, collagen deposition and the imbalance of uric acid transporters. RNA-sequencing revealed a key mechanism involved in the protective effects on HN mice was related to PI3K/AKT/NF-κB pathway. Western blot also confirmed that FTZ diminished the phosphorylation of AKT and p65 in HN mice. FTZ prevents renal injury, inflammation and fibrosis in HN mice via promoting uric acid excretion and inhibiting PI3K/AKT/NF-κB signaling pathway. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Neuroprotection, learning and memory improvement of a standardized extract from Renshen Shouwu against neuronal injury and vascular dementia in rats with brain ischemia.
- Author
-
Wan, Li, Cheng, Yufang, Luo, Zhanyuan, Guo, Haibiao, Zhao, Wenjing, Gu, Quanlin, Yang, Xu, Xu, Jiangping, Bei, Weijian, and Guo, Jiao
- Subjects
- *
CEREBRAL ischemia , *THERAPEUTICS , *REPERFUSION injury , *VASCULAR dementia , *ALTERNATIVE medicine , *ANIMAL behavior , *ANIMAL experimentation , *BIOPHYSICS , *BRAIN , *DOSE-effect relationship in pharmacology , *HERBAL medicine , *HIPPOCAMPUS (Brain) , *HISTOLOGICAL techniques , *LEARNING , *RESEARCH methodology , *CHINESE medicine , *MEMORY , *MICROSCOPY , *NEURONS , *ORAL drug administration , *RATS , *STAINS & staining (Microscopy) , *STATISTICAL significance , *DESCRIPTIVE statistics , *PREVENTION - Abstract
Ethnopharmacological relevance The Renshen Shouwu capsule (RSSW) is a patented Traditional Chinese Medicine (TCM), that has been proven to improve memory and is widely used in China to apoplexy syndrome and memory deficits. To investigate the neuroprotective and therapeutic effect of the Renshen Shouwu standardized extract (RSSW) on ischemic brain neuronal injury and impairment of learning and memory related to Vascular Dementia (VD) induced by a focal and global cerebral ischemia-reperfusion injury in rats. Material and methods Using in vivo rat models of both focal ischemia/reperfusion (I/R) injuries induced by a middle cerebral artery occlusion (MCAO), and VD with transient global brain I/R neuronal injuries induced by a four-vessel occlusion (4-VO) in Sprague–Dawley (SD) rats, RSSW (50,100, and 200 mg kg −1 body weights) and Egb761® (80 mg kg −1 ) were administered orally for 20 days (preventively 6 days+therapeutically 14 days) in 4-VO rats, and for 7 days (3 days preventively+4 days therapeutically) in MCAO rats. Learning and memory behavioral performance was assayed using a Morris water maze test including a place navigation trial and a spatial probe trial. Brain histochemical morphology and hippocampal neuron survival was quantified using microscope assay of a puffin brain/hippocampus slice with cresyl violet staining. Results MCAO ischemia/reperfusion caused infarct damage in rat brain tissue. 4-VO ischemia/reperfusion caused a hippocampal neuronal lesion and learning and memory deficits in rats. Administration of RSSW (50, 100, and 200 mg/kg) or EGb761 significantly reduced the size of the insulted brain hemisphere lesion and improved the neurological behavior of MCAO rats. In addition, RSSW markedly reduced an increase in the brain infarct volume from an I/R-induced MCAO and reduced the cerebral water content in a dose-dependent way. Administration of RSSW also increased the pyramidal neuronal density in the hippocampus of surviving rats after transient global brain ischemia and improved the learning and memory ability of rats with 4-VO induced vascular dementia in a dose-dependent manner. Conclusions The in vivo results suggested that RSSW has significant neuroprotective effects against MCAO and 4-VO I/R injury and a therapeutic effect on cognitive disorders in VD rats. RSSW also improved the learning and memory ability of VD rats. These results convincingly demonstrated that RSSW may be useful to prevent and treat ischemia/reperfusion injury and vascular dementia disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against atherosclerosis by suppressing EndMT via modulating Akt1/β-catenin signaling pathway.
- Author
-
Diao, Hongtao, Cheng, Jiawen, Huang, Xueying, Huang, Bingying, Shao, Xiaoqi, Zhao, Jingjing, Lan, Dingming, Zhu, Qing, Yan, Meiling, Zhang, Yue, Rong, Xianglu, and Guo, Jiao
- Subjects
- *
ENDOTHELIAL cells , *IN vitro studies , *BIOMARKERS , *HERBAL medicine , *IN vivo studies , *WESTERN immunoblotting , *LOW density lipoproteins , *ATHEROSCLEROSIS , *CELLULAR signal transduction , *GENE expression , *SIMVASTATIN , *BIOLOGICAL assay , *POLYMERASE chain reaction , *CHINESE medicine , *MICE , *DRUG administration , *DRUG dosage - Abstract
Fufang Zhenzhu Tiaozhi (FTZ) is a traditional Chinese herbal prescription that has been used to treat dyslipidemia, nonalcoholic fatty liver disease, atherosclerosis, diabetes and its complications in the clinic for almost ten years. Endothelial-mesenchymal transition (EndMT) is the key driver of atherosclerosis. However, the effects of FTZ on endothelial dysfunction and EndMT remain unknown. To evaluate the therapeutic effects of FTZ against EndMT and the underlying mechanisms. An in vivo model of atherosclerosis was established by feeding ApoE−/- mice with a high-fat diet (HFD). The body weight, lipid levels, plaque area, lipid deposition and EndMT were evaluated using standard assays 12 weeks after intragastric administration of FTZ and simvastatin. Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to simulate EndMT in vitro. The degree of EndMT was assessed after treating the cells with FTZ or transfection with si-Akt1. The expression levels of genes involved in EndMT were quantified by real-time PCR or western blotting. FTZ ameliorated dyslipidemia and endothelial dysfunction in the atherosclerotic mice. In addition, FTZ reduced body weight and the total cholesterol, triglycerides and low-density lipoprotein levels, and increased that of high-density lipoproteins. FTZ also upregulated the expression of endothelial markers (CD31 and VE-cadherin) and decreased that of mesenchymal markers (ɑ-SMA and FSP1), indicating that it inhibits EndMT. Knocking down Akt1 exacerbated EndMT and reversed the therapeutic effect of FTZ. FTZ delayed atherosclerosis by inhibiting EndMT via the Akt1/β-catenin pathway. [Display omitted] • EndMT is a potential target of FTZ against atherosclerosis. • FTZ plays a crucial role in regulating EndMT and stabilizing atherosclerotic plaques in ApoE−/− mice. • Inhibition of the Akt1/β-catenin signaling pathway is an underlying mechanism of the therapeutic effect of FTZ on EndMT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease.
- Author
-
Yang, Yi-Qi, Tan, Hai-Bo, Zhang, Xiao-Yu, Zhang, Yu-Zhen, Lin, Quan-You, Huang, Min-Yi, Lin, Zi-Yang, Mo, Jia-Zhi, Zhang, Yue, Lan, Tian, Bei, Wei-Jian, and Guo, Jiao
- Subjects
- *
ACUTE kidney failure prevention , *TRIGLYCERIDES , *CYTOKINES , *HERBAL medicine , *PHARMACEUTICAL encapsulation , *INFLAMMATION , *ANIMAL experimentation , *SERUM , *AMINOGLYCOSIDES , *LDL cholesterol , *CELLULAR signal transduction , *TREATMENT effectiveness , *PROTEINURIA , *CHINESE medicine , *DIABETIC nephropathies , *MICE , *DIETARY fats , *CREATININE , *PHARMACODYNAMICS - Abstract
Fufang Zhenzhu Tiaozhi capsule (FTZ) is a patented preparation of Chinese herbal medicine that has been used to treat hyperlipidemia, nonalcoholic fatty liver disease, atherosclerosis, and other glucolipid metabolic diseases (GLMDs) in the clinic for almost 10 years. However, how FTZ reduces albuminuria and attenuates diabetic kidney disease (DKD) progression is unknown. To clarify the effects of FTZ on DKD mice model and to explore the underlying mechanisms. We used streptozotocin (STZ) (40 mg/kg/d, i.p. for 5 days, consecutively) combined with a high-fat diet (HFD) to induce a DKD mouse model, followed by FTZ (1, 2 g/kg/d, i.g.) treatment for 12 weeks. Losartan (30 mg/kg/d, i.g.) was used as a positive control. Measurements of 24 h proteinuria, serum creatinine (SCr), fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) levels and expression levels of fibronectin (FN), collagen IV, inflammatory cytokines, inflammatory cells, interleukin-17A (IL-17A) and the nuclear transcription factor-κB (NF-κB) signaling pathway in the kidney were examined. FTZ effectively decreased 24 h proteinuria, Scr, FBG, TC, TG, and LDL-C levels, inhibited mesangial cell expansion, reduced FN and collagen IV accumulation, and F4/80+ macrophage cell infiltration and Ly-6G+ neutrophil infiltration in glomerulus and tubulointerstitium. Furthermore, IL-17A production and the NF-κB signaling pathway were also downregulated after the administration of FTZ. FTZ might attenuate DKD progression, and inhibited kidney inflammation and fibrosis by inhibiting the expression of RORγT and IL-17A in vivo , offering novel insights for the clinical application of FTZ. [Display omitted] • Fufang Zhenzhu Tiaozhi capsule protects against renal injury, ECM accumulation and inflammation in DKD mice. • Fufang Zhenzhu Tiaozhi capsule inhibits the RORγT/IL-17A/NF-κB signaling pathway in DKD mice. • We provided a potential clinical drug for diabetic kidney disease in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation.
- Author
-
Yan, Meiling, Li, Lun, Wang, Qing, Shao, Xiaoqi, Luo, Qingmao, Liu, Suping, Li, Yun, Wang, Dongwei, Zhang, Yue, Diao, Hongtao, Rong, Xianglu, and Guo, Jiao
- Subjects
- *
DIABETIC cardiomyopathy , *OXIDATIVE stress , *CHINESE medicine , *HERBAL medicine , *INFLAMMASOMES , *CARDIOMYOPATHIES , *CELL death , *PALMITIC acid - Abstract
Fufang Zhenzhu Tiao Zhi (FTZ) formula is a Chinese herbal preparation used in the clinical treatment of disorders of glucolipid metabolism. Given its effective actions on the regulation of lipid dysfunction and its anti-inflammatory and antioxidative effects, we designed this study to investigate the cardioprotective effect and possible mechanism of FTZ in diabetic cardiomyopathy (DCM) mice. FTZ was administered to diabetic mice by oral gavage daily at a dose of 1.2 g/kg or 2.4 g/kg bodyweight for 8 weeks. Doppler echocardiography, H&E, and WGA staining were used to evaluate cardiac function and structure in the mice. The levels of proinflammatory cytokines and lipids in serum were detected with corresponding commercial kits. Immunofluorescence staining and flow cytometry were used to detect oxidation damage and pyroptosis in myocardial cells. RT–PCR and western blotting were used to analyze the protein and mRNA expression levels of NLRP3 inflammasome-related genes. Our study indicated that FTZ improved cardiac function, attenuated heart hypertrophy, improved serum lipid and proinflammatory cytokine levels, and restrained oxidative stress and NLRP3 inflammasome-induced inflammatory activities in diabetic mouse hearts. The in vitro data suggested that FTZ suppressed intercellular lipid accumulation as well as palmitic acid (PA)-induced oxidative stress and NLRP3 inflammasome-dependent pyroptosis in cardiomyocytes. Our present findings indicate that FTZ inhibits DCM by inhibiting both oxidative stress and NLRP3 inflammasome activation induced by cardiac lipotoxicity. [Display omitted] • FTZ has a protective effect against cardiac dysfunction and hypertrophy in mice with diabetic cardiomyopathy. • FTZ alleviates mitochondrial oxidative damage and myocardial pyroptosis in mice with diabetic cardiomyopathy. • FTZ suppresses palmitic acid-induced oxidative stress and NLRP3 inflammasome-dependent pyroptosis in cardiomyocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
- Author
-
Wang, Hong, Tan, Haibo, Zhan, Wenjing, Song, Lixia, Zhang, Dongxing, Chen, Xu, Lin, Ziyang, Wang, Weixuan, Yang, Yiqi, Wang, Lexun, Bei, Weijian, and Guo, Jiao
- Subjects
- *
TRIGLYCERIDES , *FASTING , *HERBAL medicine , *FATTY liver , *ANIMAL experimentation , *PHARMACOLOGY , *SWINE , *METABOLISM , *BLOOD sugar , *TYPE 2 diabetes , *MOLECULAR biology , *CELLULAR signal transduction , *HIGH density lipoproteins , *CHINESE medicine , *INSULIN resistance - Abstract
Fufang Zhenzhu Tiaozhi formula (FTZ) of which a patented preparation of Chinese herbal medicine has been well documented with significant clinical curative effect for hyperglycemia and hyperlipidemia. Because of the complexity of the chemical constituents of Chinese herbal formulas, the holistic pharmacological mechanism of FTZ acting on type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) remains unclear. To investigate the pharmacological efficacy and mechanism of FTZ in the treatment of T2DM accompanied by NAFLD. Network pharmacology and validation in minipigs were used in this study. First, potential bioactive compounds of FTZ were identified by the traditional Chinese medicine system pharmacology technology platform (TCMSP). Then, targets of compounds were gathered using DrugBank, SwissTargetPrediction and TCMSP, while targets for T2DM and NAFLD were collected from CTD (compounds-targets-diseases network) and GeneCards. Common targets were defined as direct therapeutic targets acting on T2DM with NAFLD. In addition, crucial targets were chosen by the protein-protein interaction (PPI) network and contribution to compound-therapeutic targets in T2DM with the NAFLD network. Furthermore, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the metabolism-related signaling pathways affected by FTZ. Candidate patterns selected by network pharmacology were tested in the minipigs model of T2DM with NAFLD. Measurements of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting insulin (FINS) and fasting blood glucose (FBG) in the blood and the expression levels of proteins, including PI3K-AKT and HIF-1α, in the livers of the minipigs were followed by the administration of FTZ. A total of 116 active compounds and 82 potential targets related to T2DM and NAFLD were found. Pathway and functional enrichment analysis showed that FTZ mainly regulates metabolism-related pathways, including PI3K-AKT, HIF-1α, TNFα and MAPK. Animal experiments showed that FTZ treatment significantly reduced the serum levels of TG, TC, LDL-C and FBG, increased serum levels of HDL-C, ameliorated systemic insulin resistance (IR), and attenuated liver damage in minipigs with T2DM and NAFLD. FTZ treatment has an obviously favorable influence on hepatic steatosis and liver lipid accumulation in the histopathologic features of HE, Oil red O staining, and electron microscopy. Mechanistically, FTZ improved liver metabolism by increasing the phosphorylation of PI3K-AKT and decreasing the expression of HIF-1α. Network pharmacology was supported by experimental studies, which indicated that FTZ has demonstrated therapeutic benefits in T2DM and NAFLD by regulating the PI3K-AKT and HIF-1α signaling pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease.
- Author
-
Song, Lixia, Zhang, Dongxing, Guo, Caijuan, Gu, Zhanhui, Wang, Lexun, Yao, Yu Si, Wang, Hong, Zeng, Zhihuan, Wang, Weixuan, Yang, Yiqi, Bei, Weijian, Rong, Xianglu, and Guo, Jiao
- Subjects
- *
CORONARY disease , *CHINESE medicine , *TUMOR necrosis factors , *CORONARY artery stenosis , *BLOOD lactate - Abstract
Diabetes mellitus (DM) is a major risk factor for coronary heart disease (CHD). Previous research has reported that the Fufang-Zhenzhu-Tiaozhi (FTZ) formula has obvious effects on the treatment of dyslipidemia and hyperglycemia. In the present study, we intended to establish a convenient DM-CHD model in minipigs and investigated the protective effect of FTZ against myocardial injury and its mechanism. The DM-CHD model was established by a high-fat/high-sucrose/high-cholesterol diet (HFSCD) combined with balloon injury in the coronary artery. Subsequently, sixteen Wuzhishan minipigs were assigned to three groups: control group, model group, and FTZ group. The model group and FTZ group were given a HFSCD, while the control group was given a normal diet (ND). FTZ was given with meals in the FTZ group. During this time, biochemical parameters, such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG), were measured by using testing kits. Insulin (INS) was determined by ELISA, and the homeostasis model assessment index of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance levels. After FTZ administration, the plasma levels of lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB), and cardiac troponin I (cTnI) were measured by using ELISA kits to evaluate myocardial injury. Coronary artery stenosis was analyzed by angiographic and HE staining. Myocardial ischemia was assayed with electrocardiogram (ECG). Moreover, cytokines, including interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), and tumor necrosis factor-alpha (TNF-α), were measured by ELISA kits to assess inflammation. The myocardial tissue was collected, and the pathological morphology was observed by transmission electron microscopy (TEM), HE staining, and Masson staining. Western blots were used to detect the expression of PI3K, AKT, p-AKT, p-NF-κB, and NF-κB. A DM-CHD model in minipigs with glucose-lipid metabolism disorder, coronary artery incrassation and myocardial damage was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ effectively inhibited coronary artery incrassation and protected the myocardium against injury in DM-CHD minipigs. FTZ decreased proinflammatory cytokine levels and upregulated the protein expression of the PI3K/Akt pathway in the myocardium. A novel DM-CHD model in minipigs was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ has a protective effect against myocardial injury in DM-CHD by inhibiting inflammation and activating the PI3K/AKT signaling pathway. [Display omitted] • A novel DM-CHD model was successfully established through balloon injury in the coronary artery combined with HFSCD. • FTZ can alleviate the disorder of glucose metabolism in minipigs of DM-CHD. • FTZ effectively inhibited the coronary artery incrassation and protected myocardium against injured in minipigs of DM-CHD. • FTZ alleviates inflammation cytokine levels and up-regulated the protein expression of the PI3K/Akt pathway in myocardium. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Traditional Chinese Medicine formula FTZ protects against polycystic ovary syndrome through modulating adiponectin-mediated fat-ovary crosstalk in mice.
- Author
-
Xu, Ying, Tang, Jialing, Guo, Qianyu, Xu, Yidan, Yan, Kaixuan, Wu, Lihong, Xie, Kang, Zhu, Anming, Rong, Xianglu, Ye, Dewei, and Guo, Jiao
- Subjects
- *
ANIMAL experimentation , *HERBAL medicine , *INSULIN resistance , *CHINESE medicine , *MICE , *POLYCYSTIC ovary syndrome , *ADIPONECTIN , *LETROZOLE - Abstract
FuFang ZhenZhu TiaoZhi (FTZ) is a hospitalized traditional Chinese medicine herbal formula with documented metabolic benefits. Polycystic ovary syndrome (PCOS) characterized by ovarian dysfunction and insulin resistance represents one of the most common endocrine disorders in close association with metabolic dysfunction in premenopausal women. Aim of The Study: The present study aimed to investigate the preventive effect of FTZ on letrozole-induced experimental PCOS and its associated insulin resistance in mice. Prepubertal female mice in the experimental groups (letrozole and FTZ) received continuous infusion of letrozole (50 μg/day) for 35 days. FTZ was administrated to mice by oral gavage daily at dosage of 2.892 g/kg body weight for 5 weeks. All groups of mice were fed a high-fat diet (HFD). Ovary and adipose tissue were collected from all mice after 5 weeks and adiponectin, testosterone, estradiol, and luteinizing hormone level determined. Letrozole-induced morphological changes in the ovary, including a decreased number of corpora lutea and antral follicles, and increased cystic follicles, were significantly attenuated in FTZ-treated mice. Additionally, FTZ treatment notably reversed PCOS-related disruption of estrous status. PCOS-related insulin resistance was markedly alleviated. Mechanistically, FTZ treatment notably enhanced circulating level and transcriptional abundance of adiponectin in adipose tissue, thereby orchestrating fat-ovary crosstalk. Our data collectively demonstrate that FTZ exerted preventive benefits in an experimental model of PCOS, at least partially by potentiating the production of adiponectin from adipose tissues. This suggests that FTZ is a promising treatment for PCOS. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Fufang-Zhenzhu-Tiaozhi capsule ameliorates rabbit's iliac artery restenosis by regulating adiponectin signaling pathway.
- Author
-
Li, Tudi, Zhang, Rendan, Liu, Yuhong, Yao, Yusi, Guo, Jiao, and Zeng, Zhihuan
- Subjects
- *
ILIAC artery , *TRANSLUMINAL angioplasty , *WESTERN immunoblotting , *DIGITAL subtraction angiography , *CHINESE medicine , *BLOOD lipids , *CREATINE kinase - Abstract
• We find that FTZ up-regulates adiponectin signaling pathway for the first time. • This study explores the potential side effects of FTZ for the first time. • We validated that adiponectin was a new target for the prevention and treatment of vascular restenosis firstly. Fufang-Zhenzhu-Tiaozhi Capsule (FTZ), a traditional Chinese medicine, has been shown obvious effects on the treatment of dyslipidemia and atherosclerosis. The aim of this study was to evaluate whether FTZ can ameliorate rabbit iliac artery restenosis after angioplasty by regulating adiponectin signaling pathway. The rabbit iliac artery restenosis model was established through percutaneous iliac artery transluminal balloon angioplasty and a high-fat diet. Twenty eight male New Zealand rabbits (8-week-old) were divided into sham operation group (Group Ⅰ), model group (Group Ⅱ), atorvastatin group (Group Ⅲ) and FTZ group (Group Ⅳ), with 7 rabbits in each group. Vascular stenosis was analyzed with Digital Subtraction Angiography. Level of adiponectin (APN), and inflammatory factor including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) as well as monocyte chemoattractant protein-1 (MCP-1) was measured by Enzyme Linked Immunosorbent Assay; and injured iliac artery was collected for Hematoxylin-eosin staining and Western Blotting detection of expression of peroxisome proliferator-activated receptor-alpha (PPAR-α), adenosine 5′-monophosphate -activated protein kinase (AMPK) and phosphorylated adenosine 5′-monophosphate -activated protein kinase (p-AMPK). Besides, we evaluated FTZ's safety for the first time. Percutaneous iliac artery transluminal balloon angioplasty and high-fat diet result in inflammatory response and restenosis. Compared with Group Ⅱ, iliac artery restenosis was significantly ameliorated in Group Ⅳ (P < 0.05). Treated with FTZ, serum lipids were significantly decreased (P < 0.01) , while the level of APN was elevated significantly (P < 0.01). Western blotting detection of the injured iliac artery showed that the expressions of PPAR-α, AMPK and p-AMPK were significantly increased in Group Ⅳ (P < 0.01) than that in Group Ⅱ. Besides, before and after taking drugs, liver and kidney function indicators, creatine kinase, as well as measurement of echocardiography were of no statistical difference in four groups (P > 0.05). FTZ could effectively reduce serum lipids and ameliorate rabbit's iliac artery restenosis after angioplasty, and its mechanism may be related to activation of APN signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Renshen Shouwu extract enhances neurogenesis and angiogenesis via inhibition of TLR4/NF-κB/NLRP3 signaling pathway following ischemic stroke in rats.
- Author
-
Li, Yuping, Liang, Wenyi, Guo, Caijuan, Chen, Xu, Huang, Yijian, Wang, Hong, Song, Lixia, Zhang, Dongxing, Zhan, Wenjing, Lin, Ziyang, Tan, Haibo, Bei, Weijian, and Guo, Jiao
- Subjects
- *
ANIMAL experimentation , *CELL receptors , *CELLULAR signal transduction , *CEREBRAL arteries , *CEREBRAL ischemia , *GINSENG , *HIGH performance liquid chromatography , *CHINESE medicine , *ORAL drug administration , *PROTEOLYTIC enzymes , *RATS , *STROKE , *WESTERN immunoblotting , *DNA-binding proteins , *SIGNAL peptides , *PATHOLOGIC neovascularization - Abstract
Renshen Shouwu extract (RSSW) is a patented Traditional Chinese Medicine included in Chinese Pharmacopoeia for neurasthenia, forgetfulness, insomnia, inappetence and excessive fatigue. Our previous study had demonstrated the neuroprotective effect of RSSW against ischemic stroke in rats with middle cerebral artery occlusion (MCAO). However, its underlying mechanism remains unknown. In this study, we investigated the neurogenesis and angiogenesis effects of RSSW in ischemic stroke rats, and further revealed its underlying mechanism focused on TLR4/NF-κB/NLRP3 signaling pathway. Firstly, active compounds of RSSW were determined by High Performance Liquid Chromatography (HPLC). Secondly, Middle cerebral artery occlusion (MCAO) was performed to induce ischemic stroke in rats and 2, 3, 5-Triphenyltetrazolium chloride (TTC) staining was employed to evaluate whether MCAO surgery was successfully established. Neurological deficit evaluation was conducted according to the Zea Longa' method. Then, we explored the neurogenesis and angiogenesis effects after oral administration of RSSW (50 mg/kg, 100 mg/kg) in MCAO-induced rats by Immunofluorescence Staining. Moreover, the proteins involved in TLR4/NF-κB/NLRP3 signaling pathway (TLR4, p–NF–κB p65, NF-κB p65, NLRP3, pro-IL-1β, IL-1β, pro-Caspase-1, Caspase-1) were determined by western blotting. It was observed that RSSW treatment significantly increased the number of newborn neurons and brain microvessel density (MVD) after ischemic stroke. What's more, RSSW treatment significantly downregulated TLR4, p–NF–κB p65/p65, NLRP3, pro-IL-1β, IL-1β, pro-Caspase-1, Caspase-1 proteins involved in TLR4/NF-κB/NLRP3 signaling pathway. RSSW enhances neurogenesis and angiogenesis via inhibition of TLR4/NF-κB/NLRP3 inflammatory signaling pathway following ischemic stroke in rats. Hence, RSSW may be a promising Chinese Medicine for the treatment of ischemic stroke. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.